Beyond Air, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Beyond Air, Inc. (Nasdaq: XAIR) is a commercial-stage medical device and biopharmaceutical company that develops the LungFit platform, a nitric oxide generator and delivery system which produces nitric oxide from ambient room air for inhalation therapies targeting respiratory diseases, infections, and other conditions. The company's core products include LungFit PH, an FDA-approved system for persistent pulmonary hypertension of the newborn in hospital NICU settings delivering low-concentration nitric oxide up to 80 ppm; LungFit GO, an investigational at-home device for high-concentration nitric oxide (80 to 400 ppm) treatments of nontuberculous mycobacteria lung infections and chronic obstructive pulmonary disease; and LungFit PRO, an investigational hospital system for high-concentration antimicrobial applications including viral community-acquired pneumonia. Beyond Air also advances drug candidates such as BA 102, a neuronal nitric oxide synthase inhibitor for autism spectrum disorder, Phelan-McDermid syndrome, and Alzheimer's disease through its NeuroNOS segment; and ultra-high concentration nitric oxide therapies (>10,000 ppm) via affiliate Beyond Cancer for cutaneous and solid tumors, including monotherapy and combinations with anti-PD-1 or anti-CTLA-4. Founded in 2011 and headquartered in Garden City, New York, the company operates primarily in the United States with expanding international distribution; it changed its name from AIT Therapeutics, Inc. in June 2019. Recent developments include expansion of the LungFit PH global distribution network to 18 countries through new agreements in France, Turkey, Romania, Morocco, Japan, South Korea, and Costa Rica as of fiscal second quarter 2026; partnerships with Getz Healthcare for 10 Asian markets including Australia and New Zealand, and The Hebrew University of Jerusalem for neurological disorder treatments; a grant from the Cystic Fibrosis Foundation supporting LungFit GO trials; and ongoing FDA discussions for cardiac surgery indications and next-generation LungFit PH2 system approval.
Company News
Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
Beyond Air, Inc. (XAIR) Q1 2027 Earnings Call Transcript
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
Beyond Oil Expands Commercial Rollout to a Second Ownership Group of Top-Tier U.S. Supermarket Brand
Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Beyond Air, Inc. (XAIR) Q4 2026 Earnings Call Transcript
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting
Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
Beyond Air, Inc. (NASDAQ:XAIR) Short Interest Update
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript